Wire · opportunities
Teleflex Interventional leader sees resorbables as 'next frontier' of PCI
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 October 2026 · Fusion42 review
Teleflex's Freesolve RMS, a resorbable magnesium scaffold for PCI, received FDA Breakthrough Device designation in October 2026, expediting its U.S. regulatory review. The device, already CE marked and available in several regions, aims to provide vessel support during drug delivery and subsequently dissolve, addressing a gap in permanent stent solutions.
This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it between 22 Oct 2026 and 26 Oct 2026.
◆ ◆ The Wire takeaway
You face a sudden opening in cardiovascular device innovation as Teleflex pushes resorbable stents past regulatory gates. If you work in PCI tools or vessel treatment, this is your chance to reframe permanent implants as obsolete and explore resorbable alternatives now gaining traction.
◆ Coverage
2 sources · first reported 22 Oct 2026 · latest 26 Oct 2026
◆ Related on Wire
◆ Topics